Floatz logo

PRILOCAINE

Leukemia

Federal University of Minas GeraisSmall moleculePhase 4 / ApprovedDormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

123 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
Daunorubicin
Richard Stone, MD
Phase 3BB
Idarubicine
Affiliated Hospital of Nantong University
Phase 3BB
ASPARAGINASE
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB

View all 50 →

Same molecule, other indications

PRILOCAINE is also rated in:

Leukemia-LymphomaDormant
BB
Indicative ·
69 / 100
View asset →
Migraine DisordersDormant
BB
Indicative ·
64 / 100
View asset →
Non Hodgkin LymphomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →